Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Trastuzumab + Chemotherapy (for HER2-positive)
Treatment for Stomach cancer
Typical Dosage: Trastuzumab: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks (with chemotherapy)
Effectiveness
85%
Safety Score
35%
Clinical Trials
30
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Trastuzumab: 8 mg/kg loading dose, then 6 mg/kg every 3 weeks (with chemotherapy)
Time to Effect
2-4 weeks
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$105,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.7
Outcome-Based Costs
Cost per Responder
$223,404
Cost per Remission
$2,100,000
Comparison vs Chemotherapy alone
Cost Difference
+$60,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Trastuzumab + Chemotherapy (for HER2-positive) Outcomes
for Stomach cancer
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+47%
Remission Rate
+5%
Common Side Effects
Chemotherapy-related (Nausea, Neutropenia, Fatigue)
+80%
Cardiac dysfunction/CHF
+10%
Infusion-related reactions
+15%
Diarrhea
+30%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
4 active trials recruiting for Trastuzumab + Chemotherapy (for HER2-positive) in Stomach cancer
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478RECRUITINGPHASE3
726 participants
INTERVENTIONAL
New Haven, United States +249 more
Started: Feb 27, 2025
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
NCT05993234RECRUITING
257 participants
OBSERVATIONAL
Klagenfurt, Austria +75 more
Started: Dec 5, 2023
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
NCT06253650RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Milan, Italy
Started: Mar 1, 2024
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738ACTIVE NOT RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Phoenix, United States +26 more
Started: Sep 15, 2020
Completed Clinical Trials
9 completed trials for Trastuzumab + Chemotherapy (for HER2-positive) in Stomach cancer
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
NCT01928290COMPLETEDPHASE2
67 participants
INTERVENTIONAL
St Louis, United States
Started: Nov 8, 2013
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
NCT02004769COMPLETEDPHASE2
67 participants
INTERVENTIONAL
Guangzhou, China
Started: Nov 1, 2013
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
NCT03615326COMPLETEDPHASE3
738 participants
INTERVENTIONAL
Los Angeles, United States +191 more
Started: Oct 5, 2018
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
NCT04281576COMPLETEDNA
28 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: Dec 19, 2019
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
NCT01774786COMPLETEDPHASE3
780 participants
INTERVENTIONAL
Fort Myers, United States +171 more
Started: Jun 10, 2013
Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer
NCT02725424COMPLETEDPHASE2
180 participants
INTERVENTIONAL
Beijing, China
Started: Aug 1, 2015
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
NCT02954536COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Basking Ridge, United States +7 more
Started: Nov 3, 2016
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
NCT01461057COMPLETEDPHASE2
30 participants
INTERVENTIONAL
Brussels, Belgium +23 more
Started: Dec 6, 2011
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
NCT01041404COMPLETEDPHASE3
584 participants
INTERVENTIONAL
Adelaide, Australia +141 more
Started: Sep 1, 2005
Showing 20 of 34 total trials